西妥昔单抗联合伊立替康治疗晚期胃癌对患者核因子κB、正常上皮细胞特异性1蛋白表达及生存期的影响

目的研究西妥昔单抗联合伊利替康治疗晚期胃癌对患者核因子κB(NF-κB)、正常上皮细胞特异性1(NES1)蛋白表达及生存期的影响。方法将80例晚期胃癌患者根据治疗方法不同分为研究组和对照组各40例,研究组利用西妥昔单抗联合伊立替康治疗,对照组单独利用西妥昔单抗治疗,比较两组患者癌胚抗原(CEA)NF-κB、NES1表达情况、治疗效果、不良反应发生情况和生存情况。结果研究组治疗后有效率为85.00%(34/40),与对照组的70.00%(28/40)比较,差异无统计学意义(P﹥0.05)。治疗前,两组患者CEA、NES1、NF-κB水平比较,差异均无统计学意义(P﹥0.05)。治疗后,研究组患者CEA水平明显低于对照组,NES1、NF-κB水平明显高于对照组,差异均有统计学意义(P﹤0.01)。研究组患者不良反应总发生率为20.00%(8/40),低于对照组的42.50%(17/40),差异有统计学意义(P﹤0.05)。研究组治疗后1年中位生存期为8.26个月(95%CI:6.154~9.985),长于对照组的6.54个月(95%CI:5.112~8.013),差异有统计学意义(P﹤0.05);研究组治疗后复发4例,少于对照组的10例,差异有统计学意义(P﹤0.05)。结论西妥昔单抗联合伊立替康治疗晚期胃癌具有良好的疗效,提高了NF-κB、NES1表达水平,降低了不良反应发生率并延长患者的生存期,对晚期胃癌患者的诊疗有指导意义。

Expression of nuclear factor-κB and normal epithelial cell specific 1,and the survival in advanced gastric cancer patients treated with cetuximab combined with irinotecan

Objective To study the effect of cetuximab combined with irinotecan on the expression of nuclear factorkappa B(NF-κB)and normal epithelial cell specific 1(NES1)and on survival time in patients with advanced gastric cancer.Method Eighty patients with advanced gastric cancer treated by varying therapies were included in the analysis as study group and control group,with 40 cases in each.The study group was treated with cetuximab plus irinotecan,and the control group was administered with cetuximab monotherapy.The expression of carbohydrate antigen(CEA),NF-κB and NES1,therapeutic effects,incidence of adverse reactions,and survival were compared between the two groups.Result The response rate in the study group was 85.00%(34/40),and was merely numerically higher than that in control group at 70.00%(28/40),with no significant differences noted(P>0.05).The level of CEA,NES1,and NF-κB were similar in the two groups before treatment(P>0.05).While after treatment,CEA was lower,and NES1 and NF-κB were higher in study group compared to control group,the changes were statistically significant(P<0.01).Study group patients were observed with an overall incidence of adverse reactions of 20.00%(8/40)which was markedly lower than the 42.50%(17/40)in control group(P<0.05).The 1-year median survival time of study group patients was 8.26 months(95%CI:6.154-9.985),and was evidently extended compared to control group at 6.54 months(95%CI:5.112-8.013)(P<0.05);there were 4 cases versus 10 cases of recurrence in study group and control group after treatment,respectively(P<0.05).Conciusion The evidence generated in the study suggests that cetuximab combined with irinotecan in the treatment of patients with advanced gastric cancer demonstrates fairly good efficacy,with improved expression of NF-κB and NES1,and lowered incidence of complications,thereby extending patients’survival time,and thus informs the diagnosis and treatment of advanced gastric cancer.